Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Investing Cash Flow

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Investing Cash Flow of -$7.94 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-02.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2024-04-02

  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was -$13.82M, a 107.65% decline year-over-year.
  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-09-30 was $5.69M.
  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-06-30 was $285.24K.
  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-03-31 was -$100.00K.
  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$7.94M, a 104.39% decline from fiscal 2022.
  • CERO THERAPEUTICS HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $180.84M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 4 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 7 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2023-12-31-$13.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02
-$8.13M
derived: sum of 2 quarters · filed 2024-04-02
-$7.84M
derived: sum of 3 quarters · filed 2024-04-02
-$7.94M
10-K · filed 2024-04-02
2023-09-30$5.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$5.97M
derived: sum of 2 quarters · filed 2023-11-09
$5.87M
10-Q · filed 2023-11-09
$186.58M
derived: sum of 4 quarters · filed 2024-04-02
2023-06-30$285.24K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$185.24K
10-Q · filed 2023-08-14
$180.90M
derived: sum of 3 quarters · filed 2024-04-02
2023-03-31-$100.00K
10-Q · filed 2023-05-12
$180.61M
derived: sum of 2 quarters · filed 2024-04-02
2022-12-31$180.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02
$180.84M
10-K · filed 2024-04-02
2022-09-30$128.49K
10-Q · filed 2023-11-09
2022-03-31$0.00
10-Q · filed 2023-05-12
2021-12-31-$178.50M
10-K · filed 2023-03-24
2021-09-30$0.00
10-Q · filed 2022-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05